Medpace designs studies, signs up hospitals, enrols patients, runs the tests and prepares the file for the regulator, mostly for small biotech companies.
The company · 2 · What exactly does it sell?
Service fees, plus costs passed through
What it earns
59.0%service fees for running trials
41.0%costs passed through at cost
About 29%each from obesity and cancer trials
The passed-through costs, like travel and hospital fees, earn Medpace nothing but swell its revenue.
The company · 3 · How does it make money?
Paid as each trial moves forward
$3.17Bof signed work not yet done
$873.4Mnew work signed last quarter
About 24%of signed work turned to sales a quarter
Medpace is paid as each trial progresses, so today's sales come from work signed earlier.
Is it a good business? · 4 · What gives it an edge?
For a small sponsor, delay costs most
About $800,000
lost sales per day of delay
11.5%
its 2025 service revenue growth
4.3%
IQVIA's trial business growth
Nothing locks a client in, though; the record has to be earned trial by trial.
Is it a good business? · 5 · What is the catch?
Larger rivals bid for the same work
IQVIAlarger, slower-growing
ICONrevenue grew 0.8% in 2025
Listed rivals: ICLR · IQV · FTRE · TMO
When a big drug maker buys a small biotech, its trials can move inside.
Is it a good business? · 6 · What does its record show?
Fast growth, fewer shares, more profit
Sales, $B
1.1
1.5
1.9
2.1
2.5
2.8
Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025last 12 mo
Sales$1.14B → $2.84Brevenue, 2021 to the past year
Profit17% → 21%operating profit per $1
Shares37.7M → 28.4Mshares, after buying them back
Overheads fell as a share of revenue, though passed-through costs blur the ratios.
Is it a good business? · 7 · How much room is there to grow?
The market it serves cannot be measured
About $145Ba year of trial spending
About 2,185mid- and late-stage trials started, 2025
About $1.5BMedpace's own service revenue
Nobody publishes how much small sponsors spend on outsourced trials.
Is it a good business? · 8 · Who is in charge?
The founder still runs it
1992August Troendle founded Medpace
19.6% → 19.1%his stake, cut by heavy sales this autumn
His autumn sales were not under a pre-set plan. About 2% of revenue comes from companies linked to him.
The story right now · 9 · Why does biotech funding matter?
Small biotechs spend what investors give them
0.88new work signed per $1 of sales in early 2026, as cancellations spiked
1.2 timesnew work signed against sales
About 29%of work in obesity trials
Small biotechs have no sales of their own; they fund trials with investors' money. When funding dries up or a drug fails, trials get cancelled.
The story right now · 10 · Why must growth slow?
Working faster through orders cannot last
Signed work piles up$3.17B.
Worked off faster24% a quarter, not 18%.
Sales jumpAhead of orders.
Pace returns to normalGrowth slows.
Unless new orders climb faster than sales, revenue must slow to the pace orders allow.
The story right now · 11 · What changed lately?
New work signed outran sales
$873.4Mnew work signed in the quarter
+8.5%revenue, to $716.0M
$3.17Bsigned work, up 5.6%
Solid quarter
Cancellations ran at the high end of normal, blamed on failed drugs rather than funding; most analysts now rate the shares a hold.
The story right now · 12 · What is everyone arguing about?
Scare over, or arithmetic ahead?
Many investors think
A fine business at a full price, scare over
We think
Revenue ran ahead of orders, so growth must slow
Against us: record orders and eight quarters beating forecasts.
The price and our view · 13 · What is a share worth?
The price leaves little room if orders stall
$408what we think a share is worth · the last close is of that
$408our value
Attractive below $327
Neutral
Unattractive above $490
$252gloomy: growth halves, less kept per $1
$408our estimate: experts' path, then slowing
$506sunny: growth beats the forecast by a quarter
Value per share in three futures. None is a prediction of the share price.
We estimate what a share is worth from the cash the business should earn over many years. Our rule: buy only when the price is at least a fifth below our estimate, as a cushion for being wrong.
The price and our view · 14 · How could we be wrong?
Orders can vanish fast
Orders can vanishBiggest
Cancellations spike.
Obesity trials winding downShowing now
The growth engine fades.
Biotechs need moneyWatch
Funding drives orders.
Obesity share of ordersUnknown
Not disclosed.
A few clients matter more than before, and the founder decides.
The price and our view · 15 · How will we know?
February tests orders and 2027
New work stays above 1.2 times salesGood sign
Cancellations fall backGood sign
Biotech funding dries upBad sign
FEB 20278
Fourth-quarter 2026 results, 8 February. Companies report every three months; each report is a test of the story.
Our view also changes on price alone: if the shares fall to within a fifth of our estimate, we move to Neutral.
The price and our view · 16 · So, what do we think?
A share-taking trial runner, priced for steady orders
$408our value
Attractive below $327
Neutral
Unattractive above $490
UnattractiveHigh conviction
Medpace runs complete drug trials for small biotechs, winning work from bigger rivals while buying back shares. But orders can vanish fast, obesity trials are winding down and revenue has outgrown orders.
↑ ↓ to move · C for contents
What it does
More about the company
Who it is
Medpace is a contract research organisation: a company drug makers hire to run the trials that prove a medicine works and is safe. It designs the study, signs up hospitals, enrols patients, runs the lab tests and scans, and prepares the file for the regulator.
Its customers are mostly small biotech companies, 82% of 2025 revenue, which usually have one promising drug and no trial staff. Without Medpace they would hire their own team, or juggle a big rival such as IQVIA or ICON with several specialist suppliers.
How it makes money
Medpace is paid by the trial, as the work gets done. About 59% of 2025 revenue was fees for its own staff's work, and 41% was hospital and travel costs it passes on to the sponsor at little or no profit.
New trials are won as awards and then sit in an order book, called backlog, of about $3.0B. Clients can cancel on about 30 days' notice, so the order book is a list of likely work, not a promise.
Growth and profit
What growth costs
Growth has been making Medpace more profitable. Overheads take a smaller share of each sales dollar than five years ago, pay in shares stays small, and staff numbers grew far slower than revenue, though pass-through costs flatter that last comparison.
Its record
The numbers
Is it growing?Steady
Sales grew 20% over the twelve months to Sep 2026, about the same pace as the 20% in the year to Dec 2025.
Is it profitable?Strong
Operating margin is 21%, up from 18% in the year to Dec 2023.
How steady is it?Uneven
Yearly sales growth has ranged from +12% to +29% over the last 5 years.
Does it earn good returns?Strong
Each dollar put into the business earns 114% a year after tax, up from 20% in the year to Dec 2021.
Is it making cash?Strong
It turned 24% of sales into free cash, $668M over the last twelve months.
Is profit turning into cash?Real cash
Free cash flow was 1.3 times net income.
Are shares being diluted?Shrinking
The share count fell 25% in 4.8 years, and pay in shares costs 0.8% of sales.
Why it wins
The evidence
For a small sponsor, delay is the expensive thing. Researchers at Tufts estimate one day's delay costs a drug about $800,000 of lost sales, far more than the gap between two firms' fees. So sponsors pick the firm they trust to finish on time.
Medpace's record with small sponsors seems to be winning: in 2025 its own service revenue grew 11.5%, while IQVIA's trial business grew 4.3% and ICON's revenue 0.8%. Nothing locks a client in, though; the record has to be re-earned on every trial.
Who could beat it
The rivals in full
IQVIA, ICON, Thermo Fisher's PPD and Fortrea run the same kind of trials, are larger, and bid for the same awards. The other threat is the client itself: when a big drug maker buys a small biotech, its trials can move to the buyer's own staff.
Each rival
ICONICLR
The whole outsourced trial, bid against Medpace for the same award; ICON is larger and mainly serves big pharmaceutical companies.
IQVIA Research & Development SolutionsIQV
The whole outsourced trial, with IQVIA's patient data to pick sites; the largest CRO.
FortreaFTRE
Full-service and functional trial work, often sold on price after its spin-off from Labcorp.
PPD, part of Thermo FisherTMO
The whole outsourced trial, sold with Thermo Fisher's lab and manufacturing services.
Sponsors' own trial teamsin house
The outsourcing itself, when a sponsor that is bought by a large drug maker moves its trials in-house.
How big it could get
The market and who has signed
The market
Drug and biotech companies started about 2,185 mid- and late-stage trials in 2025, up slightly after three years of decline, inside roughly $145B a year of trial spending. Medpace's own service revenue was about $1.5B of that.
Nobody publishes how much small sponsors spend on outsourced trials, so the market Medpace actually serves cannot be measured in dollars.
Who runs it
Leaders, pay and the cash
Who runs it
August Troendle founded Medpace in 1992 and still runs it as chief executive and chairman. He owns about 19% of the company, though he sold heavily this autumn near the highs, without a pre-set plan. The long-serving president left in April 2026 and has not been replaced.
Half of the executives' yearly bonus rides on profit against the company's own forecast and a quarter on revenue; none on orders. Medpace also earns about 2% of revenue from drug companies linked to Troendle.
What they did with the money
Medpace spends its spare cash on its own shares. It bought $912.9M of stock in 2025 and $294.7M more in the second quarter of 2026, with no debt and no acquisitions, so the share count has fallen about a fifth since 2021.
The last report
The latest report
Medpace signed $873M of new work in Q3, more than its sales
What it did to the thesis Solid quarter
The call answers the open question on cancellations: contained, not gone. The 2027 comment sits close to the growth line we watch.
The report
In the September 2026 quarter revenue grew 8.5% to $716.0M and earnings per share rose to $4.84 from $3.86. Medpace signed $873.4M of new work, about 1.2 times its sales, and its backlog of future work grew 5.6% to $3.17B. Management raised the earnings forecast and narrowed the sales forecast to the same midpoint.
On the call the chief executive said cancellations were toward the high end of normal but not a worry, and blamed failed drugs, not lack of funding. He gave no 2027 forecast until February, saying it is close to what analysts expect.
What's happening now
The background
The shares have swung hard this year. They fell to $393.42 in April after cancellations spiked, then recovered above $600 as orders came back. Most analysts now rate them a hold, and the founder sold near the top.
The next test is the fourth-quarter report in February, with the first 2027 forecast. Management says its 2027 view rises month by month but depends on fourth-quarter orders and cancellations.
Where we disagree
Both sides in full
The market
Most analysts rate Medpace a fine business at a full price, and treat the record second-quarter orders as the end of this year's scare.
We believe
Revenue has run ahead of orders, so growth must slow unless orders keep climbing; the price leaves little room if they do not.
The argument
Our worry is arithmetic, not quality. Medpace has been converting about 24% of its order book into revenue each quarter against about 18% historically, and management expects that to drift down. If it does, revenue can only keep growing if the order book grows faster than its recent 4.9%.
The evidence against us is real: orders hit a record in the second quarter, management says its pipeline of not-yet-booked work grew faster than the order book, and it has beaten forecasts eight quarters in a row.
What it's worth
How we value it
Valued on the analysts' revenue path for three years, each later year closing 30% of the gap to 4%, on official operating profit with stock pay a cost and tax paid in full; the thesis's own evidence is the check on that path.
What the price assumes
Sales growth in the first year, then slowing as ours does, at the same profit per sale.
The price assumed
29.5%
Our estimate
5%
Measured at the close of
6 Nov 2026
The three cases
Bear case$252
Growth runs at half the analysts' path, 2%, 4% and 4%, the margin settles a fifth lower at 18.0%, and new capital earns only the 8% rate: the downturn test.
Our value$408
Revenue grows 5%, 8% and 7% over three years, the analysts' path (C51), then fades toward 4%, closing 30% of the gap each year; the margin moves to 22.5%, the analysts' year-three figure after stock pay.
Bull case$506
Growth runs a quarter above the analysts' path, 6%, 10% and 9%, the margin reaches 24.7%, and new capital earns 15%.
What could go wrong
Every risk
The risks
Orders can vanish fast
Clients can cancel on about 30 days' notice, and early 2026 showed how quickly cancellations can turn a strong quarter weak.
Obesity trials are winding down
Metabolic work, mostly obesity drugs, carried much of 2025's growth, and the largest programmes are now shrinking.
A few clients matter more
The ten largest customers were about 40% of revenue in the year to June 2026, up from 35% in 2025.
Small biotechs need money
Most clients depend on investors to fund their trials; when funding dries up, trials are delayed or cancelled.
The founder decides
Troendle controls about a fifth of the shares, sells at will, has no named second-in-command, and has business ties with some clients.
What we still do not know
How much of the order book sits with the few large obesity-drug clients, and how fast it runs off.
Whether Medpace's win rate against IQVIA and ICON has recovered after falling in 2025.
Whether AI tools at drug companies will cut the amount of trial work they hire out, or its price.
Who will run the company after its 69-year-old founder.
What changes our view
Every route to a new view
Every route to a new view
→ Neutral
The share price falls to about $490, back within 20% of what we think the business is worth.
→ Attractive
The share price falls to about $327, 80% of what we think the business is worth.
→ Attractive
The order book grows 10% or more on a year earlier. In the same quarter, new orders reach 1.15 times revenue or more.
The next test
It supports the case if
Net book-to-bill of 1.05 or more and backlog growth of 5% or more in Q4, with cancellations described as normal and the 2027 revenue guide implying growth of 5% or more.
It pressures the case if
Net book-to-bill below 1.05, backlog growth below 5%, cancellations again described as elevated, or a 2027 guide implying growth below 5%.
We would also be wrong if
The 2027 forecast, due about February, implies revenue growth below 5%.
The ten largest customers reach more than 45% of revenue.
The verdict
Scores and how we weighed it
The scores
Growth
3 of 4
Business quality
3 of 4
Financial position
4 of 4
Execution record
3 of 4
Per share capture
4 of 4
Potential
2 of 4
Risk profile
3 of 4
Valuation
1 of 4
Evidence quality
3 of 4
How we weighed it
ValueNegative
The price sits above our value and above the bull case.
BusinessPositive
It wins work from bigger rivals, with no debt and steady buybacks.
GrowthMixed
Bookings must replace finishing obesity trials before growth slows.
RisksNegative
Clients cancel on short notice, obesity trials wind down and a few clients matter more.
RivalsPositive
In the middle of its rivals on profit while growing faster.
The groupMixed
It sits in none of our ranked groups; biotech funding moves it.
Latest newsMixed
The last report showed cancellations contained, not gone.
In plain words
Our estimate of value
We forecast how much cash the business can earn over the next ten years and beyond, then ask what that stream is worth today to an investor who wants an 8% yearly return. We do it three times: a gloomy future, an expected one and a sunny one. We call a share Attractive only when its price is at least 20% below the expected estimate, and Unattractive when it is 20% above.